** Drug developer GH Research's GHRS.O shares rise 5.8% to $9.5 premarket
** Co says its lead experimental drug met the main goal in two mid-stage studies testing it as a treatment for postpartum depression and bipolar II disorder
** The drug, GH001, helped significantly reduce severity of depressive episodes and led to rapid antidepressant effect in the studies - GHRS
** In both trials, GH001 was well tolerated with no reported treatment-related serious side-effects - GHRS
** Bipolar II disorder is a mental health condition that causes extreme mood swings with at least one major depressive episode and at least one hypomanic episode
** Up to last close, stock up 54.3% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.